Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIFT: Brolucizumab for suboptimally controlled neovascular age-related macular degeneration
2019-004145-33Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2019
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brolucizumab in exudative macular degeneration, sponsored by Novartis. Primary endpoint: Proportion of patients with no disease activity at Week 16. Started Dec 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-004145-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004145-33.